

**Alameda Alliance for Health**  
1240 South Loop Road  
Alameda, CA 94502

**Piedmont Conference Room**  
*To arrange public building access, please  
contact Ashley Ragadio at 510.373.5731*

## AGENDA

ITEM	DESCRIPTION	TIME	VOTE
I)	<b>Call to order</b> <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <ul style="list-style-type: none"> <li>Agenda Overview</li> </ul>	2 min	-
II)	<b>Informational Updates</b> <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> <li>Staffing Update &amp; Governor's Executive Order Update</li> </ul>	15min	-
III)	<b>Review/ Approval of previous meeting minutes</b> <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> <li>P&amp;T Meeting Minutes from September 24th, 2019</li> </ul>	2 min	V
IV)	<b>Pharmacy Utilization Reports (Quarter 3 2019)</b> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> <li>Top 50 Drugs by Cost</li> <li>Top 100 PA Reviewed Drugs</li> </ul>		

### Consent Agenda

*Natalee Felten, PharmD, Pharmacist, PerformRx*

*Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance*

*(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)*

Monographs/Class Reviews	Changes
Blood Glucose test strips	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Vitamins for ocular health	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Conventional DMARDs	<ul style="list-style-type: none"> <li>Change Otezla from NF to F-PA (also in psoriasis class review)</li> </ul>
Allergenic extracts	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Medication Request Guidelines	Changes
Specialty Biological Agents for Ankylosing Spondylitis	<ul style="list-style-type: none"> <li>Add Taltz as co-preferred product due to new indication</li> </ul>
Butorphanol (Stadol NS)	<ul style="list-style-type: none"> <li>Minor formatting and wording changes</li> </ul>
Oral and Non-Oral Contraceptives	<ul style="list-style-type: none"> <li>Removal of brand names, adjustment of brand/generic status</li> </ul>
HP Acthar Criteria	<ul style="list-style-type: none"> <li>Correct &lt; symbol</li> </ul>
Growth Hormone	<ul style="list-style-type: none"> <li>Removal of discontinued products, addition of new products</li> </ul>
Lupron Depot and Lupron Depot-Ped	<ul style="list-style-type: none"> <li>Removal of gender dysphoria language from the criteria statement section</li> </ul>
Ranolazine (Ranexa)	<ul style="list-style-type: none"> <li>Change brand/generic status</li> </ul>

20  
min

V  
(on  
each  
topic)

Tolcapone (Tasmar)	• Wording changes for flow and revision of brand/generic status
Oral Anti-Fungals	• Correction of fluconazole suspension strength
Alosetron (Lotronex)	• Update brand/generic status, reword first bullet point for clarity
Immunizations	• Correct Havrix and Vaqta to 2 fills per lifetime, update Prevnar-13 from 2 fills per lifetime to 1 fill per lifetime
Injectable/Specialty Medications	• Correction of later approval to 12 months
Viberzi (eluxadoline)	• Minor phrasing change of criteria statement
Topical Diclofenac	• Minor phrasing change of criteria statement
Step Therapy Exception	• No changes
Prior Authorization Exception	• No changes
Endari	• No changes
Thalomid	• No changes
Topiramate (Topamax) sprinkles	• No changes
Gattex (teduglutide)	• No changes
<b>Pharmacy Policy and Procedures</b>	<b>Changes</b>
P&P RX 001-011	No changes
<b>Interim Formulary changes</b>	
• See p. in packet	

### Pharmacy Policies & Procedures Updates

#### No Changes per Annual Review for the following Policies & Procedures

- RX-001 Pharmaceutical Operating Processes Summary.
- RX-002 Prior Authorization Review Process
- RX-003 Exception Review Process
- RX-004 Formulary Management
- RX-005 P&T Committee Roles and Scope
- RX-006 Pharmacy Services Staff Description
- RX-007 Pharmaceutical Patient Safety
- RX-008 PBM Delegated Audit Oversight
- RX-009 Pharmaceutical Emergency Supply Provision
- RX-010 Drug Utilization Management
- RX-011 Decision and Notification Requirements

### ADJOURN TO CLOSED SESSION *(Pursuant to California Government Code Title 5, §54954.5(h))*

**Discussion will Concern:** Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes  
**Estimated Date of Public Disclosure:** December 2019 (formulary changes only; no trade secrets will be disclosed).

#### V) New Business

Natalee Felten, PharmD, Pharmacist, PerformRx  
Rahel Negash, PharmD, Pharmacist – Alameda Alliance

- Otezla for Bechet's disease MRG
- Rayaldee MRG
- Korlym MRG
- Eosinophilic Asthma Agents MRG
- Updates to the 90 day maintenance list

60  
min

V  
(on  
each  
topic)

**Class Reviews, Monographs, and Recommendations**

*Natalee Felten, PharmD, Pharmacist, PerformRx*

*Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance*

1. Phosphate binders
2. Hormone replacement therapy
3. Topical acne
4. Conventional agents for psoriasis
5. Urinary tract antispasmodics

**RECONVENE IN OPEN SESSION**

ITEM	DESCRIPTION	TIME	VOTE		
VI)	<b>Summary of Closed Session</b> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i>	2 min	-		
VII)	<b>Medication Request Guidelines</b> <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i>				
	<table border="0"> <tr> <td style="vertical-align: top;"> <ol style="list-style-type: none"> <li>1. Hepatitis C Medications criteria</li> <li>2. Cystic Fibrosis Agents</li> <li>3. Inhaled Corticosteroids/Long-Acting Beta-Agonists (ICS/LABA) Combinations</li> <li>4. Oral and Injectable Oncology Medications</li> <li>5. Antibiotic Eye Drops</li> <li>6. Entresto (sacubitril/valsartan)</li> <li>7. Lidocaine (Lidoderm)</li> <li>8. Mesalamine</li> <li>9. Corticosteroids for Ulcerative Colitis and Crohn’s disease</li> <li>10. Fentanyl Citrate</li> <li>11. Proton Pump Inhibitors (PPIs)</li> <li>12. Temazepam (Restoril)</li> </ol> </td> <td style="vertical-align: top;"> <ol style="list-style-type: none"> <li>13. Testosterone Agents</li> <li>14. Drugs for Gender Dysphoria For Less Than 21 Years Old</li> <li>15. Drugs for Gender Dysphoria For At Least 21 Years Old</li> <li>16. Ophthalmic Anti-Inflammatory Agents</li> </ol> </td> </tr> </table>	<ol style="list-style-type: none"> <li>1. Hepatitis C Medications criteria</li> <li>2. Cystic Fibrosis Agents</li> <li>3. Inhaled Corticosteroids/Long-Acting Beta-Agonists (ICS/LABA) Combinations</li> <li>4. Oral and Injectable Oncology Medications</li> <li>5. Antibiotic Eye Drops</li> <li>6. Entresto (sacubitril/valsartan)</li> <li>7. Lidocaine (Lidoderm)</li> <li>8. Mesalamine</li> <li>9. Corticosteroids for Ulcerative Colitis and Crohn’s disease</li> <li>10. Fentanyl Citrate</li> <li>11. Proton Pump Inhibitors (PPIs)</li> <li>12. Temazepam (Restoril)</li> </ol>	<ol style="list-style-type: none"> <li>13. Testosterone Agents</li> <li>14. Drugs for Gender Dysphoria For Less Than 21 Years Old</li> <li>15. Drugs for Gender Dysphoria For At Least 21 Years Old</li> <li>16. Ophthalmic Anti-Inflammatory Agents</li> </ol>	15 min	V
<ol style="list-style-type: none"> <li>1. Hepatitis C Medications criteria</li> <li>2. Cystic Fibrosis Agents</li> <li>3. Inhaled Corticosteroids/Long-Acting Beta-Agonists (ICS/LABA) Combinations</li> <li>4. Oral and Injectable Oncology Medications</li> <li>5. Antibiotic Eye Drops</li> <li>6. Entresto (sacubitril/valsartan)</li> <li>7. Lidocaine (Lidoderm)</li> <li>8. Mesalamine</li> <li>9. Corticosteroids for Ulcerative Colitis and Crohn’s disease</li> <li>10. Fentanyl Citrate</li> <li>11. Proton Pump Inhibitors (PPIs)</li> <li>12. Temazepam (Restoril)</li> </ol>	<ol style="list-style-type: none"> <li>13. Testosterone Agents</li> <li>14. Drugs for Gender Dysphoria For Less Than 21 Years Old</li> <li>15. Drugs for Gender Dysphoria For At Least 21 Years Old</li> <li>16. Ophthalmic Anti-Inflammatory Agents</li> </ol>				
VIII)	<b>Informational Updates on New Developments in Pharmacy</b> <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i>	5 min	-		
	<ul style="list-style-type: none"> <li>• New Product Review</li> </ul>				
IX)	<b>Public Comment</b>	2 min	-		
X)	<b>Adjournment</b>				
	<ul style="list-style-type: none"> <li>• P&amp;T Committee Member Forms</li> </ul>	-	-		

**ACTION / FOLLOW-UP ITEMS**

ITEM	DUE DATE	RESPONSIBLE

FUTURE P&T MEETINGS	
NEXT MEETING	2020 P&T MEETINGS
March 17 <sup>th</sup> , 2020	March 17 <sup>th</sup> , 2020
	June 16 <sup>th</sup> , 2020
	September 16 <sup>th</sup> , 2020
	December 15 <sup>th</sup> , 2020

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

**Note:** Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or [hlee@alamedaalliance.org](mailto:hlee@alamedaalliance.org) at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.